RGEN
RGEN
NASDAQ · Life Sciences Tools & Services

Repligen Corp

$123.46
-2.97 (-2.35%)
As of May 9, 1:12 AM ET ·
Financial Highlights (FY 2026)
Revenue
743.05M
Net Income
49.21M
Gross Margin
52.6%
Profit Margin
6.6%
Rev Growth
-2.7%
D/E Ratio
0.26
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 52.6% 52.6% 33.3% 33.3%
Operating Margin 7.5% 6.7% 6.8% 6.5%
Profit Margin 6.6% 6.3% 7.1% 6.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 743.05M 763.67M 4.59B 4.00B
Gross Profit 391.22M 402.07M 1.53B 1.33B
Operating Income 55.51M 51.34M 311.12M 261.18M
Net Income 49.21M 45.52M 325.04M 256.90M
Gross Margin 52.6% 52.6% 33.3% 33.3%
Operating Margin 7.5% 6.7% 6.8% 6.5%
Profit Margin 6.6% 6.3% 7.1% 6.4%
Rev Growth -2.7% -2.7% +1.3% +8.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 719.39M 719.39M 1.77B 1.35B
Total Equity 2.79B 2.79B 3.56B 3.35B
D/E Ratio 0.26 0.26 0.50 0.40
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 137.61M 134.36M 499.02M 399.89M
Free Cash Flow 285.62M 226.18M